KMT2D is frequently mutated in DLBCL (~ 30% of de novo cases, including both germinal center B-cell and activated B-cell subtypes and follicular lymphoma (~ 90%)) [23]. Here, KMT2D is linked to diffuse large B-cell lymphoma.